SG11201804320QA - Pharmaceutical composition containing 2-{4-[n-(5,6- diphenylpyrazin-2-yl)-n-isopropylamino]butyloxy}-n- (methylsulfonyl)acetamide - Google Patents

Pharmaceutical composition containing 2-{4-[n-(5,6- diphenylpyrazin-2-yl)-n-isopropylamino]butyloxy}-n- (methylsulfonyl)acetamide

Info

Publication number: SG11201804320QA
Authority: SG; Singapore
Prior art keywords: diphenylpyrazin; isopropylamino; methylsulfonyl; acetamide; butyloxy
Prior art date: 2015-12-02

Application number

SG11201804320QA

Other languages

English (en)

Inventor

Shouji Furuta

Hironori Mukai

Original Assignee

Nippon Shinyaku Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-12-02

Filing date

2016-12-01

Publication date

2018-06-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59014064&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201804320Q(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-12-01 Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd

2018-06-28 Publication of SG11201804320QA publication Critical patent/SG11201804320QA/en

Links

239000008194 pharmaceutical composition Substances 0.000 title 1
QXWZQTURMXZVHJ-UHFFFAOYSA-N selexipag Chemical compound C=1C=CC=CC=1C1=NC(N(CCCCOCC(=O)NS(C)(=O)=O)C(C)C)=CN=C1C1=CC=CC=C1 QXWZQTURMXZVHJ-UHFFFAOYSA-N 0.000 title 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 2
239000007787 solid Substances 0.000 abstract 2
235000010355 mannitol Nutrition 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Pulmonology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Inorganic Chemistry (AREA)
Diabetes (AREA)
Hematology (AREA)
Vascular Medicine (AREA)
Oil, Petroleum & Natural Gas (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

SG11201804320QA 2015-12-02 2016-12-01 Pharmaceutical composition containing 2-{4-[n-(5,6- diphenylpyrazin-2-yl)-n-isopropylamino]butyloxy}-n- (methylsulfonyl)acetamide SG11201804320QA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2015236034		2015-12-02
PCT/JP2016/085822 WO2017098998A1 (ja)	2015-12-02	2016-12-01	２－｛４－［ｎ－（５，６－ジフェニルピラジン－２－イル）－ｎ－イソプロピルアミノ］ブチルオキシ｝－ｎ－（メチルスルホニル）アセトアミドを含有する医薬組成物

Publications (1)

Publication Number	Publication Date
SG11201804320QA true SG11201804320QA (en)	2018-06-28

Family

ID=59014064

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11201804320QA SG11201804320QA (en)	2015-12-02	2016-12-01	Pharmaceutical composition containing 2-{4-[n-(5,6- diphenylpyrazin-2-yl)-n-isopropylamino]butyloxy}-n- (methylsulfonyl)acetamide

Country Status (32)

Country	Link
US (2)	US10821108B2 (de)
EP (3)	EP4501404A3 (de)
JP (1)	JP6825574B2 (de)
KR (1)	KR102759845B1 (de)
CN (1)	CN108289890B (de)
AU (1)	AU2016366073B2 (de)
BR (1)	BR112018009534B1 (de)
CL (1)	CL2018001464A1 (de)
CO (1)	CO2018006834A2 (de)
DK (1)	DK4331607T3 (de)
EC (1)	ECSP18049108A (de)
ES (1)	ES3030325T3 (de)
FI (1)	FI4331607T3 (de)
HR (1)	HRP20250572T1 (de)
HU (1)	HUE071411T2 (de)
IL (2)	IL310203A (de)
LT (1)	LT4331607T (de)
MX (1)	MX385595B (de)
MY (1)	MY198164A (de)
PE (1)	PE20181072A1 (de)
PH (1)	PH12018501161B1 (de)
PL (1)	PL4331607T3 (de)
PT (1)	PT4331607T (de)
RS (1)	RS66791B1 (de)
RU (1)	RU2735547C2 (de)
SA (1)	SA518391686B1 (de)
SG (1)	SG11201804320QA (de)
SI (1)	SI4331607T1 (de)
TW (1)	TWI750143B (de)
UA (1)	UA124002C2 (de)
WO (1)	WO2017098998A1 (de)
ZA (1)	ZA201804387B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JOP20190204A1 (ar)	2017-03-08	2019-09-05	Actelion Pharmaceuticals Ltd	تركيبة صيدلانية تشتمل على سيليكسيباغ
TW201922230A (zh)	2017-11-16	2019-06-16	日商日本新藥股份有限公司	控釋製劑
AU2019225516A1 (en) *	2018-02-21	2020-10-08	Nippon Shinyaku Co., Ltd.	Granular composition, production method for granular composition, and dissolution property improvement method for granular composition
US12427145B2 (en)	2019-02-03	2025-09-30	Innovate Therapeutics Llc	Controlled release pharmaceutical composition of Selexipag or it's active metabolite
US20210069187A1 (en) *	2019-05-11	2021-03-11	RK Pharma Solutions LLC	Stable pharmaceutical composition of Selexipag
PH12022550937A1 (en) *	2019-10-23	2023-06-14	Actelion Pharmaceuticals Ltd	Pharmaceutical composition comprising selexipag
CN114051644B (zh)	2019-11-25	2024-03-15	埃赛克斯古河电磁线日本有限公司	绝缘电线、线圈和电气/电子设备
WO2021206159A1 (ja) *	2020-04-10	2021-10-14	日本新薬株式会社	固形製剤及びその製造方法
CN112220770B (zh) *	2020-12-17	2021-04-09	上海翰森生物医药科技有限公司	司来帕格的药物组合物及其制备方法
WO2022240378A1 (en) *	2021-05-11	2022-11-17	Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi	A stable pharmaceutical composition comprising selexipag

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP3145431B2 (ja)	1991-08-20	2001-03-12	日本酸素株式会社	安定同位体標識蛋白質の製造法および試薬キット
JP3126683B2 (ja) *	1996-04-16	2001-01-22	武田薬品工業株式会社	Ｄ−マンニトールおよびその製造法
US20010001106A1 (en)	1996-04-16	2001-05-10	Tomohiro Yoshinari	D-mannitol and its preparation
WO2001089520A2 (en)	2000-05-19	2001-11-29	Progenics Pharmaceuticals, Inc.	Dehydroascorbic acid formulations and uses thereof
ATE260281T1 (de)	2000-08-03	2004-03-15	Pfizer Prod Inc	Diazacyclooctanverbindungen und ihre therapeutische verwendung
TWI316055B (de) *	2001-04-26	2009-10-21	Nippon Shinyaku Co Ltd
JP2006504696A (ja)	2002-09-20	2006-02-09	メルク　エンド　カムパニー　インコーポレーテッド	インテグリン受容体アンタゴニストのマンニトール製剤
JP2004269513A (ja)	2003-02-19	2004-09-30	Rohto Pharmaceut Co Ltd	固形製剤
US7112393B2 (en)	2003-07-29	2006-09-26	Canon Kabushiki Kaisha	Non-magnetic toner
CA2687794C (en)	2007-05-28	2015-01-27	Jin Satomi	Spherical particle of crystalline mannitol
FR2918566B1 (fr)	2007-07-11	2009-10-09	Pierre Fabre Medicament Sa	Composition pharmaceutique stable d'un sel hydrosoluble de vinflunine.
EP2209501B1 (de)	2007-10-12	2011-12-14	AstraZeneca AB	Zibotentan Zusammensetzung mit Mannitol und Mikrokristalliner Zellulose
ES2393640T3 (es)	2008-02-13	2012-12-26	Dainippon Sumitomo Pharma Co., Ltd.	Comprimidos bucodisgregables
ES2817557T3 (es)	2008-02-28	2021-04-07	Nippon Shinyaku Co Ltd	Inhibidor de fibrosis
WO2009154246A1 (ja)	2008-06-19	2009-12-23	日本新薬株式会社	勃起不全治療剤
PL2292231T3 (pl)	2008-06-23	2016-03-31	Nippon Shinyaku Co Ltd	Środek terapeutyczny przeciw zwężeniu kanału kręgowego
WO2009157397A1 (ja)	2008-06-23	2009-12-30	日本新薬株式会社	非ステロイド性抗炎症剤投与に伴う腸管傷害治療剤
CN102065864B (zh) *	2008-06-23	2012-11-21	日本新药株式会社	炎性肠病治疗剂
MX346318B (es)	2009-06-26	2017-03-15	Nippon Shinyaku Co Ltd	Cristales.
ES2733998T3 (es)	2012-10-29	2019-12-03	Cardio Incorporated	Agente terapéutico específico de enfermedad pulmonar
CN103690496B (zh)	2013-12-27	2015-04-01	哈药集团生物工程有限公司	一种含有奥扎格雷钠的冻干药物组合物

2016
- 2016-12-01 DK DK23214939.3T patent/DK4331607T3/da active
- 2016-12-01 LT LTEP23214939.3T patent/LT4331607T/lt unknown
- 2016-12-01 MX MX2018006343A patent/MX385595B/es unknown
- 2016-12-01 MY MYPI2018702097A patent/MY198164A/en unknown
- 2016-12-01 HR HRP20250572TT patent/HRP20250572T1/hr unknown
- 2016-12-01 AU AU2016366073A patent/AU2016366073B2/en active Active
- 2016-12-01 TW TW105139756A patent/TWI750143B/zh active
- 2016-12-01 PT PT232149393T patent/PT4331607T/pt unknown
- 2016-12-01 SG SG11201804320QA patent/SG11201804320QA/en unknown
- 2016-12-01 JP JP2017555036A patent/JP6825574B2/ja active Active
- 2016-12-01 RU RU2018123304A patent/RU2735547C2/ru active
- 2016-12-01 EP EP24221055.7A patent/EP4501404A3/de active Pending
- 2016-12-01 SI SI201631900T patent/SI4331607T1/sl unknown
- 2016-12-01 EP EP23214939.3A patent/EP4331607B1/de active Active
- 2016-12-01 HU HUE23214939A patent/HUE071411T2/hu unknown
- 2016-12-01 RS RS20250427A patent/RS66791B1/sr unknown
- 2016-12-01 PE PE2018001060A patent/PE20181072A1/es unknown
- 2016-12-01 PL PL23214939.3T patent/PL4331607T3/pl unknown
- 2016-12-01 BR BR112018009534-6A patent/BR112018009534B1/pt active IP Right Grant
- 2016-12-01 EP EP16872896.2A patent/EP3384911A4/de not_active Withdrawn
- 2016-12-01 WO PCT/JP2016/085822 patent/WO2017098998A1/ja not_active Ceased
- 2016-12-01 UA UAA201807264A patent/UA124002C2/uk unknown
- 2016-12-01 CN CN201680068849.XA patent/CN108289890B/zh active Active
- 2016-12-01 US US15/777,711 patent/US10821108B2/en active Active
- 2016-12-01 PH PH1/2018/501161A patent/PH12018501161B1/en unknown
- 2016-12-01 FI FIEP23214939.3T patent/FI4331607T3/fi active
- 2016-12-01 ES ES23214939T patent/ES3030325T3/es active Active
- 2016-12-01 KR KR1020187017182A patent/KR102759845B1/ko active Active
- 2016-12-01 IL IL310203A patent/IL310203A/en unknown
2018
- 2018-05-17 IL IL259461A patent/IL259461A/en unknown
- 2018-05-28 SA SA518391686A patent/SA518391686B1/ar unknown
- 2018-05-31 CL CL2018001464A patent/CL2018001464A1/es unknown
- 2018-06-29 ZA ZA2018/04387A patent/ZA201804387B/en unknown
- 2018-06-29 EC ECSENADI201849108A patent/ECSP18049108A/es unknown
- 2018-06-29 CO CONC2018/0006834A patent/CO2018006834A2/es unknown
- 2018-07-25 US US16/044,821 patent/US10828298B2/en active Active

Also Published As

Publication number	Publication date
PL4331607T3 (pl)	2025-06-16
US20180325895A1 (en)	2018-11-15
PE20181072A1 (es)	2018-07-04
US20180333413A1 (en)	2018-11-22
MX385595B (es)	2025-03-18
WO2017098998A1 (ja)	2017-06-15
CO2018006834A2 (es)	2018-07-10
RS66791B1 (sr)	2025-06-30
EP4501404A2 (de)	2025-02-05
ECSP18049108A (es)	2018-10-31
US10821108B2 (en)	2020-11-03
ES3030325T3 (en)	2025-06-27
EP4331607A3 (de)	2024-05-29
UA124002C2 (uk)	2021-07-07
JPWO2017098998A1 (ja)	2018-09-20
RU2018123304A3 (de)	2020-04-02
SA518391686B1 (ar)	2024-03-03
NZ742784A (en)	2024-08-30
SI4331607T1 (sl)	2025-06-30
CA3005169A1 (en)	2017-06-15
RU2018123304A (ru)	2020-01-09
AU2016366073B2 (en)	2021-08-26
EP4331607A2 (de)	2024-03-06
LT4331607T (lt)	2025-06-10
AU2016366073A1 (en)	2018-06-14
TW201720444A (zh)	2017-06-16
RU2735547C2 (ru)	2020-11-03
US10828298B2 (en)	2020-11-10
MY198164A (en)	2023-08-08
CL2018001464A1 (es)	2018-10-19
PT4331607T (pt)	2025-05-22
EP4331607B1 (de)	2025-04-30
ZA201804387B (en)	2020-12-23
PH12018501161B1 (en)	2024-07-03
CN108289890B (zh)	2021-04-27
JP6825574B2 (ja)	2021-02-03
IL259461A (en)	2018-07-31
KR102759845B1 (ko)	2025-01-23
IL310203A (en)	2024-03-01
MX2018006343A (es)	2018-08-01
HUE071411T2 (hu)	2025-08-28
EP3384911A4 (de)	2019-05-15
TWI750143B (zh)	2021-12-21
KR20180081141A (ko)	2018-07-13
DK4331607T3 (da)	2025-05-19
HRP20250572T1 (hr)	2025-07-04
EP3384911A1 (de)	2018-10-10
FI4331607T3 (fi)	2025-06-03
EP4501404A3 (de)	2025-05-07
CN108289890A (zh)	2018-07-17
PH12018501161A1 (en)	2019-01-21
BR112018009534B1 (pt)	2023-11-07
BR112018009534A2 (pt)	2018-11-06

Publication	Publication Date	Title
SA518391686B1 (ar)	2024-03-03	{4- [n- (5، 6- داي فينيل بيرازين -2- يل) –n- تركيبة صيدلانية تحتوي على 2- –n- أيزوبروبيل أمينو] بيوتيل أوكسي} (ميثيل سيلفونيل) أسيتاميد
PH12016501310B1 (en)	2022-07-06	Pharmaceutical compositions comprising azd9291
PH12020550703A1 (en)	2021-04-26	Sulfonamide compounds and use thereof
EP3359241A4 (de)	2019-06-26	Formulierungen von pthrp-analoga, transdermale pflaster dafür und verwendungen davon
JO3452B1 (ar)	2020-07-05	بنزاميدات أمينو اريل مغاير كمثبطات كيناز
CL2016002169A1 (es)	2017-02-24	Inhibidores de diacilglicerol aciltransferasa 2 para uso en el tratamiento de trastornos metabólicos y relacionados.
MX2020011478A (es)	2020-12-07	Formas solidas de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il) -1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida y sus composiciones farmaceuticas y usos.
EP4327880A3 (de)	2024-05-22	Feste form von ribociclibsuccinat
WO2014153495A9 (en)	2015-04-23	Novel stat3 inhibitors
GEP201706673B (en)	2017-05-25	Compositions containing chondroitin sulphate, proteolytic enzymes and sulphydryl compounds for improving the bioavailability of chondroitin sulphate
SA518390920B1 (ar)	2021-12-14	مركبات فينوكسي أسيتاميد معالجة بإضافة حلقة
PH12017501832A1 (en)	2018-04-23	Stabilized pharmaceutical composition
EA201591155A1 (ru)	2016-01-29	Фармацевтическая композиция, содержащая n-[3-хлор-4-(3-фторбензилокси)фенил]-6-[5({[2-(метилсульфонил)этил]амино}метил)-2-фурил]хиназолин-4-амин или его фармацевтически приемлемые соль, сольват или сольватированную соль
BR112018002138A2 (pt)	2018-09-11	composto 2-(5 s-metil-2-oxo-4r-fenil-pirrolidin-1-il)-acetamida, uso, composição farmacêutica e método para a profilaxia ou o tratamento de convulsões
PH12018500946A1 (en)	2018-11-12	Pharmaceutical composition containing, as active ingredient, 7-azaindolin-2-one derivative or pharmaceutically acceptable salt thereof